Quick Summary — OMCL scores higher on quality with 8.0/10 vs PRVA's 7.6/10. OMCL trades at $41.91 while PRVA trades at $20.80. Both analyzed daily using SEC EDGAR data across 13 institutional models.
OMCL scores higher with a 8.0/10 quality rating vs PRVA's 7.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
At $41.91, OMCL trades +20.6% above its Bayesian DCF fair value of $33.27, while PRVA at $20.80 trades +32.0% above its estimate of $14.14. PRVA shows a wider gap between price and intrinsic value.
OMCL earns a Quality of Company score of 8.0/10 compared to PRVA's 7.6/10. The scores are closely matched, indicating similar fundamental quality profiles. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
OMCL carries a LOW value trap risk (25/100) while PRVA shows SAFE risk (18/100). Both companies show manageable value trap risk, suggesting their current valuations are not artificially depressed by fundamental deterioration.
Both OMCL and PRVA operate in Health Information Services, which has 46 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare OMCL vs PRVA differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.